Copenhagen, 31 March 2010 - During March 2010, NeuroSearch A/S (NEUR) has
increased the share capital with the issue of 174,439 new shares of DKK 20
nominal value each at a price of DKK 156.04 per share as a consequence of the
exercise of warrants granted to the Board of Directors, the Executive
Management and other employees in 2005.

Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on
Issuers' Disclosure Obligations, it is hereby announced that at the end of
March 2010 the total nominal value of the NeuroSearch A/S share capital is DKK
491,078,940 distributed on 24,553,947 shares with a nominal value of DKK 20
each and corresponding to 491,078,940 votes.

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, tel: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103

About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil®
(pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.